<div><div></div><div>Azitra reported a net loss of $3.9 million for the quarter ended March 31, 2026, and held $10.1 million in cash and cash equivalents as of that date. R&amp;D expense was $1.6 million and G&amp;A expense was $2.4 million for the quarter. The company highlighted clinical and platform progress including expansion of ATR-04 trial sites and a new U.S. patent for ATR-12.Financial Highlights<ul><li>Net loss: $3.9 million for the quarter ended March 31, 2026 (compared to $3.1 million in the comparable period of 2025).</li><li>Research and development expense: $1.6 million for the quarter ended March 31, 2026 (compared to $1.25 million in Q1 2025).</li><li>General and administrative expense: $2.4 million for the quarter ended March 31, 2026 (compared to $1.85 million in Q1 2025).</li><li>Cash and cash equivalents: $10.1 million as of March 31, 2026.</li><li>Loss per share, basic and diluted: $(0.25) for the quarter ended March 31, 2026 (vs. $(1.55) in the comparable period of 2025).</li></ul>Business Highlights<ul><li>Clinical expansion: Added MD Anderson Cancer Center as a clinical site for the Phase 1/2 ATR-04 trial targeting EGFR inhibitor–associated rash to enhance patient access and trial execution.</li><li>Product development milestones: ATR-12 (lead candidate for Netherton syndrome) received a new U.S. patent and is being evaluated in a Phase 1b trial with topline data anticipated in H2 2026.</li><li>Advancement of ATR-04: First patient dosed in the Phase 1/2 ATR-04 trial; topline data from the first cohort expected in H2 2026.</li><li>Preclinical progress: ATR-01 showed positive preclinical data demonstrating delivery of functional filaggrin and repair of damaged model skin; IND-enabling studies continue in 2026.</li><li>New cosmeceutical initiative: Launched programs leveraging proprietary filaggrin protein and peptide technologies for cosmetic and consumer markets, with repeat-application explanted skin results due mid-2026 and a planned human cosmetic application study in Q3 2026.</li></ul>Original SEC Filing: Azitra, Inc. [ AZTR ] - 8-K - May. 12, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

AZTR

ARKG

Azitra reported a Q1 2026 net loss of $3.9 million, with cash and equivalents totaling $10.1 million. R&D expenses were $1.6 million, and G&A expenses were $2.4 million. The company expanded its ATR-04 trial sites and received a new U.S. patent for ATR-12, with topline data expected in H2 2026. The first patient has been dosed in the ATR-04 trial, and preclinical progress for ATR-01 is ongoing. A new cosmeceutical initiative has also been launched, with results anticipated in mid-2026.

TradingView

Azitra

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials